Trial reportHuman vaccines & immunotherapeutics2026
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
Trial report in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two-dose childhood vaccination against measles, mumps, rubella, and varicella is widely recommended. Quadrivalent (MMRV) vaccines can be used for one or both immunizations against these diseases. In some countries, e.g. the United States, only one MMRV vaccine is licensed. Availability of another MMRV vaccine could strengthen supply resilience, optimal vaccine coverage, and disease control. In this phase II, single-blind, multi-country study, healthy children aged 4-6 y, previously primed with a first dose of any combination of measles/mumps/rubella/varicella-containing vaccine(s) in their second year of life, were randomized 2:2:2:1:1 to receive one dose of a GSK investigational MMRV (MMRVNS; three formulations) or a licensed MMRV vaccine (two lots). Immunogenicity was assessed at Day 43 post-vaccination. Adverse events (AEs) were recorded up to Day 4 (solicited administration-site and systemic AEs), Day 43 (solicited systemic and unsolicited AEs), and Day 181 (serious AEs [SAEs]) post-vaccination. Of 801 participants enrolled, 796 were vaccinated and 765 completed the study. Antigen-specific antibody geometric mean concentrations and seroresponse rates were generally comparable between MMRVNS (regardless of formulation) and MMRV recipients. Administration-site pain (29.0%-39.0% of participants) and systemic drowsiness (9.0%-15.9%) were the most common solicited AEs. Unsolicited AEs (mostly upper respiratory tract infections) were reported in 18.5%-27.2% of participants. At least one SAE (none considered vaccine-related) occurred in each group. Except for one reported fatality, all SAEs resolved. Compared to the licensed standard-of-care MMRV vaccine, the investigational MMRVNS formulations generated comparable immune responses and had a similarly acceptable safety profile, when administered as second dose. These results support further clinical development of MMRVNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.